Table A1.
Table of test specificity and sensitivity results in the literature.
| References | Test Information | Specificity | Sensitivity | ||
|---|---|---|---|---|---|
| Menon et al. (2009) | Multi-modal and ultrasound for ovarian cancer; primary ovarian and tubal | 0.998 | 0.894 | ||
| Primary invasive epithelial ovarian and tubal | 0.998 | 0.895 | |||
| USS | 0.982 | 0.75 | |||
| Citing van Nagell et al. (2007) | 0.987 | 0.763 | |||
| Grim et al. (1979) | Renal vascular hypertension screening test | 0.92 | 0.93 | ||
| Weiss et al. (1985) | HTLV-III (AIDS Agent) screening test | 0.986 | 0.973 | ||
| Stoll et al. (1999) | PTSD screening test | 0.975 | 0.77 | ||
| Kulasingam et al. (2002) | HPV testing thin-layer pap | 0.824 | 0.613 | ||
| PCR | 0.788 | 0.882 | |||
| Signal amplification | 0.726 | 0.908 | |||
| Perkins et al. (2001) | Peripheral neuropathy in Diabetes clinic | Vibration (on off) | 0.99 | 0.53 | |
| Monofilament | 0.96 | 0.77 | |||
| Superficial pain | 0.97 | 0.59 | |||
| Vibration (timed) | 0.98 | 0.8 | |||
| Deeks & Altman (2004) | Obstructive airway disease and >40 pack-years smoking | 0.986 | 0.284 | ||
| Doobay & Anand (2005) | ABI and stroke | CHD | Newman et al. (1999) | 0.908 | 0.163 |
| Abbott et al. (2000) | 0.944 | 0.167 | |||
| Stroke | Newman et al. (1999) | 0.908 | 0.17 | ||
| Abbott et al. (2000) | 0.887 | 0.22 | |||
| Tsai et al. (2001) | 0.972 | 0.092 | |||
| Schiffman et al. (2000) | HPV DNA testing for cervical cancer | 0.942 | 0.771 | ||
| 0.934 | 0.748 | ||||
| Mayrand et al. (2007) | HPV for cervical cancer (conservative case) | 0.941 | 0.946 | ||
| Pap for cervical cancer (conservative case) | 0.968 | 0.554 | |||
| Sabroe et al. (1999) | Autologous serum skin tests to screen for chronic idiopathic urticaria | 0.81 | 0.65 | ||
| 0.78 | 0.71 | ||||
| Maisel et al. (2001) | B-natriuretic peptide for left ventricular dysfunction, 75 pg/mL BNP level | 0.98 | 0.86 | ||
| Shumway-Cook et al. (2000) | Probability of falls by timed up and go test | 0.87 | 0.87 | ||
| Ferreira et al. (1992) | Endomysial antibody screening for coeliac disease, four tests | 0.99 | 1 | ||
| 0.99 | 0.91 | ||||
| 0.85 | 0.91 | ||||
| 0.88 | 0.76 | ||||
| Watson et al. (2002) | Various tests for Chlamydia | PCR cervix | 1 | 0.965 | |
| LCR urine | 1 | 0.875 | |||
| EIA urine | 1 | 0.188 | |||
| EIA cervix | 1 | 0.52 | |||
| EIA cervix | 0.99 | 0.8 | |||
| DNA probe | 0.96 | 0.72 | |||
| LET urine | 0.808 | 0.778 | |||
| EIA urine | 0.99 | 0.75 | |||
| EIA cervix | 1 | 0.844 | |||
| PCR cervix | 1 | 1 | |||
| LCR urine | 1 | 0.96 | |||
| EIA urine | 1 | 0.37 | |||
| EIA cervix | 1 | 0.783 | |||
| PCR cervix | 1 | 1 | |||
| PCR cervix | 1 | 0.85 | |||
| PCR cervix | 1 | 0.953 | |||
| PCR cervix | 0.986 | 1 | |||
| PCR urine | 0.986 | 0.923 | |||
| LCR cervix | 0.997 | 0.886 | |||
| PCR, EIA cervix | 0.997 | 0.97 | |||
| LET | 0.91 | 0.41 | |||
| LCR and LET urine | 0.949 | 0.589 | |||
| PCR urine | 0.997 | 0.82 | |||
| PCR cervix | 0.998 | 0.82 | |||
| PACE2 cervix | 1 | 0.795 | |||
| PCR urine | 0.99 | 0.85 | |||
| DFA cervix | 0.96 | 0.85 | |||
| LCR urine | 1 | 0.882 | |||
| EIA | 1 | 0.84 | |||
| PCR cervix | 0.998 | 0.992 | |||
| LCR, PCR | 1 | 0.93 | |||
| LCR, PCR | 0.996 | 0.62 | |||
| DFA cervix | 0.995 | 0.778 | |||
| PCR cervix | 1 | 0.714 | |||
| EIA cervix | 1 | 0.647 | |||
| PCR urine | 0.993 | 0.895 | |||
| Arbyn et al. (2008) | Five cervical cancer screening tests (Table 3) | VIA | 0.836 | 0.887 | |
| VILI | 0.832 | 0.957 | |||
| VIAM | 0.855 | 0.826 | |||
| Pap Smear | 0.985 | 0.651 | |||
| HC2 | 0.93 | 0.721 | |||
| Legro et al. (1998) | Fasting glucose to insulin ratio to measure insulin sensitivity | 0.84 | 0.95 | ||
| Schroeder et al. (1999) | Noninvasive determination of endothelium-mediated vasodilation | Coronary artery disease | 0.81 | 0.71 | |
| Angina pectoris | 0.571 | 0.824 | |||
| Allison et al. (1996) | Four tests for colorectal-screening | Hemoccult II | 0.981 | 0.324 | |
| Hemoccult II Sensa | 0.875 | 0.712 | |||
| Hemoselect | 0.952 | 0.672 | |||
| Combined | 0.979 | 0.537 | |||
| Ewer et al. (2011) | Pulse oximetry screening for congenital heart defects | Critical cases | 0.9912 | 0.75 | |
| All major cases | 0.9916 | 0.4906 | |||
| Boppana et al. (2011) | Saliva polymerase chain reaction assay for cytomegalovirus | Liquid Saliva | 0.999 | 1 | |
| Dried Saliva | 0.999 | 0.974 | |||
| Whitlock et al. (2008) | Several colorectal cancer screening tests | 0.94 | 0.85 | ||
| 0.944 | 0.688 | ||||
| 0.91 | 0.875 | ||||
| 0.949 | 0.865 | ||||
| 0.831 | 0.667 | ||||
| 0.969 | 0.818 | ||||
| 0.971 | 0.556 | ||||
| 0.956 | 0.909 | ||||
| Cuzick et al. (2013) | Six human papillomavirus tests | BD HPV | 0.843 | 0.975 | |
| Roche Cobas | 0.845 | 0.975 | |||
| Qiagen Hybrid | 0.854 | 0.975 | |||
| Abbott real time | 0.872 | 0.95 | |||
| Gen-probe | 0.902 | 0.975 | |||
| NorChip | 0.952 | 0.714 | |||
| Donovan et al. (2013) | Various tests for gestational diabetes | 50-G OGCT | 0.86 | 0.85 | |
| 50-G OGCT | 0.84 | 0.88 | |||
| 50-G OGCT | 0.83 | 0.85 | |||
| 50-G OGCT | 0.69 | 0.81 | |||
| 50-G OGCT | 0.89 | 0.7 | |||
| 50-G OGCT | 0.77 | 0.99 | |||
| 50-G OGCT | 0.66 | 0.88 | |||
| 50-G OGCT | 1 | 0.17 | |||
| Fasting plasma glucose | 0.52 | 0.87 | |||
| Fasting plasma glucose | 0.76 | 0.77 | |||
| Fasting plasma glucose | 0.92 | 0.76 | |||
| Fasting plasma glucose | 0.93 | 0.54 | |||
| HbA 1c | 0.28 | 0.92 | |||
| HbA 1c | 0.97 | 0.12 | |||
| HbA 1c | 0.61 | 0.86 | |||
| HbA 1c | 0.21 | 0.82 | |||
| Ng et al. (2013) | MRI and mammographic screening in survivors of Hodgkin Lymphoma | Mammogram | 0.93 | 0.68 | |
| MRI | 0.94 | 0.67 | |||
| Both | 0.9 | 0.94 | |||
| Jafari et al. (2013) | Various tests for syphilis (imperfect reference) | ||||
| Determine | Serum | 0.9415 | 0.9004 | ||
| Whole Blood | 0.9585 | 0.8632 | |||
| SD Bioline | Serum | 0.9585 | 0.8706 | ||
| Whole Blood | 0.9795 | 0.845 | |||
| Syphicheck | Serum | 0.9914 | 0.7448 | ||
| Whole Blood | 0.9958 | 0.7447 | |||
| Visitect | Serum | 0.9645 | 0.8513 | ||
| Whole Blood | 0.9943 | 0.7426 | |||
| Salami et al. (2013) | Various tests for prostate cancer | Optimized | 0.9 | 0.8 | |
| Kloten et al. (2013) | Various tests for blood-based breast cancer screening | RASSF1A UTIH5 | 0.73 | 0.54 | |
| RASSF1A DKK3 | 0.75 | 0.59 | |||
| DKK3 ITIH5 | 0.94 | 0.4 | |||
| RASSF1A DKK3 ITH5 | 0.72 | 0.67 | |||
| Firnhaber et al. (2013) | Cervical cancer screening methods in HIV positive women CIN 2+ | Cytology (MD intern) | 0.681 | 0.755 | |
| HPV | 0.514 | 0.919 | |||
| Cytology (RN intern) | 0.685 | 0.654 | |||
| Teertstra et al. (2009) | Breast tomosynthesis compared to mammography for detection of cancer | Mammography | 0.883 | 0.963 | |
| Tomosynthesis | 0.867 | 0.963 | |||
| Rafferty et al. (2013) | Breast tomosynthesis compared to mammography for detection of cancer | Mammography | 0.841 | 0.655 | |
| Mammography plus | 0.892 | 0.762 | |||
| Tomosynthesis | 0.862 | 0.627 | |||
| Mammography | 0.845 | 0.787 | |||
| Mammography plus Tomosynthesis | |||||
| Catalona et al. (1991) | Prostate-specific antigen in serum screening test | Rectal examination | 0.44 | 0.86 | |
| Ultrasonography | 0.27 | 0.92 | |||
| Serum PSA | 0.59 | 0.79 | |||